Report 20 Sep 2022

Facts and Figures 2022: The Pharmaceutical Industry and Global Health

This compendium of facts and figures relating to the biopharmaceutical industry and global health aims to provide a snapshot of the work this industry undertakes today.

Read more
Statement 13 Sep 2022

IFPMA and GSCF statement at the 72nd session of the WHO Regional Committee for Europe on Strengthening health emergency preparedness, response, and resilience: learning the lessons and building back better

13 September 2022, Tel Aviv, Israel – IFPMA and GSCF welcome the opportunity to provide comments and share insights from our Covid-19 Lessons Learned report, , which highlights that swift pathogen surveillance and sharing, an enabling innovation ecosystem, and regulatory agility are among the lessons that must be preserved for future ability to fight against...

Read more
Statement 13 Sep 2022

R&D based biopharmaceutical industry statement in support of the Seventh Global Fund Replenishment

Ahead of the Global Fund Seventh Replenishment for 2024-2026, the innovative biopharmaceutical industry reaffirms its longstanding commitment to support the Global Fund mission to defeat HIV, TB, and malaria, and ensure a healthier, safer, more equitable future for all.

Read more
Report 13 Sep 2022

Fighting for what counts: Leveraging the power of collaboration to end HIV, tuberculosis, and malaria

Leveraging the power of collaboration to end HIV, tuberculosis, and malaria.

Read more
Expert insight 9 Sep 2022

The biopharmaceutical industry continues to innovate and push science forward to manage the COVID-19 pandemic and be better prepared for future global health threats

Viruses don’t stand still. And neither do we. It’s been almost two years since the administration of the first COVID-19 vaccine in December 2020 and as of September 2022, more than two thirds of people worldwide had received at least one COVID-19 vaccine dose.

Read more
Statement 7 Sep 2022

IFPMA statement at the 75th session of the WHO Regional Committee for South-East Asia on Monitoring progress and acceleration plan for NCDs

 IFPMA is delighted to be able to join this SEARO Regional Committee meeting and appreciates the opportunity to make this statement

Read more
Statement 24 Aug 2022

IFPMA statement at the 72nd session of the WHO Regional Committee for Africa: Regional strategy for health security and emergencies 2022-2030

IFPMA welcomes the opportunity to comment on the WHO AFRO region’s strategy for health security and emergencies. The innovative biopharmaceutical industry is keen to learn lessons from the COVID-19 pandemic and to work with others to ensure we are much better prepared for the next health emergency. We are not surprised by the assessment from...

Read more
External study 23 Aug 2022

COVID-19 Report on Africa – Airfinity

Prepared for IFPMA, Airfinity have authored a report detailing the  COVID-19 pandemic in Africa, with a key focus on vaccinations.

Read more
Infographic 23 Aug 2022

Increasing Equitable Access to COVID-19 Vaccines in Africa

This infographic provides an overview of the status of COVID-19 vaccines in Africa, outlining issues of inequitable distribution on the continent, factors contributing to this, and policy recommendations to ensure equitable access to vaccines in future. 

Read more
Statement 19 Jul 2022

IFPMA written statement for the second meeting of the intergovernmental negotiating body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention preparedness and response

We congratulate you on the early progress made on this important and complex work. We will share written comments in due course. At a high level, we welcome the recognition that the development of new medicines rests on the protection of intellectual property rights; that our ability to develop medical countermeasures relies on unhindered and...

Read more
Statement 19 Jul 2022

Berlin Declaration: Biopharmaceutical Industry Vision for Equitable Access in Pandemics

The innovative biopharmaceutical industry, having developed COVID-19 vaccines and treatments at record speed and in historic quantities, proposes to create a collaborative solution for more equitable rollout of vaccines, treatments and diagnostics for future pandemics. In particular, the innovative biopharmaceutical industry is willing to reserve an allocation of real-time production of vaccines, treatments and diagnostics...

Read more
Press release 19 Jul 2022

Pharma proposes to work with G7 and G20 on a joint solution for better access to vaccines and treatments around the world for future pandemics

The biopharmaceutical industry launched today the “Berlin Declaration – biopharmaceutical industry vision for equitable access in pandemics” and presents global leaders with a proposal that could help ensure the supply of pandemic vaccines, treatments and diagnostics are delivered as early as possible in future pandemics to those who need them most.

Read more